Eli Lilly Alzheimer's drug rejected by EU regulator Ruchika Sharma31 March 2025 5:20 PM ISTIndianapolis: Indianapolis-based pharmaceutical giant Eli Lilly has faced a setback as the European Union's drug regulator rejected its...
Eli Lilly Kisunla bags marketing authorization in Great Britain to treat mild cognitive impairment, mild dementia due to Alzheimer's Disease Ruchika Sharma30 Oct 2024 10:00 AM ISTIndianapolis: Eli Lilly and Company has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing...
NHS to Block Eli Lilly's Alzheimer's Drug Donanemab Over Cost Concerns: Report MD Bureau23 Oct 2024 2:43 PM ISTThe National Institute for Health and Care Excellence (NICE), which decides what drugs are available on the NHS, will rule that it is too expensive
No major concerns raised by USFDA staff on Eli Lilly Alzheimer's drug Donanemab Ruchika Sharma7 Jun 2024 2:00 PM ISTLondon: FDA examination of trial data for Eli Lilly's investigational Alzheimer's drug Donanemab uncovered no red flags but did highlight safety...
USFDA Advisory Committee to convene meeting to discuss on Eli Lilly Alzheimer's drug donanemab Ruchika Sharma8 May 2024 4:30 PM ISTThe U.S. Food and Drug Administration (FDA) will convene an in-person meeting of the Peripheral and Central Nervous System Drugs Advisory Committee...
USFDA delays decision on Eli Lilly Alzheimer's drug Donanemab Ruchika Sharma10 March 2024 4:30 PM ISTWhite said the FDA wants the expert panel to discuss some of the unique aspects of the clinical trial used in its request for a traditional FDA...
Donanemab significantly slowed clinical progression among patients with symptomatic Alzheimer disease Dr. Shravani Dali3 Oct 2023 8:00 PM ISTDonanemab significantly slowed clinical progression among patients with symptomatic Alzheimer's disease suggests a new study published in the...
Eli Lilly presents results from Phase 3 trial of Donanemab at Alzheimer's Association Conference Ruchika Sharma19 July 2023 12:39 PM ISTIndianapolis: Eli Lilly and Company has presented full results from the Phase 3 TRAILBLAZER-ALZ 2 study showing that donanemab significantly...
USFDA rejects accelerated approval for Eli Lilly Alzheimer's drug Donanemab Ruchika Sharma20 Jan 2023 1:30 PM IST"I don't think it says anything negative about the drug. It was just a manifestation of the study design," said Dr. Ronald Petersen, an Alzheimer's...
Eli Lilly hopes to launch as many as 5 new treatments next year Ruchika Sharma14 Dec 2022 3:15 PM ISTIndianapolis: Eli Lilly and Co said on Tuesday it hopes to launch as many as five new treatments next year that could drive growth through the decade...
Novel Anti-Amyloid Slows Alzheimer's Disease Progression, Finds Phase 2 Study MD Bureau17 March 2021 9:30 PM ISTA hallmark of Alzheimer's disease is the accumulation of amyloid-β (Aβ) peptide. In a recent Phase 2 trial, researchers have found that donanemab met...
